Minerva price target lowered to $5 from $7 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Minerva to $5 from $7 and keeps a Neutral rating on the shares. The pathway of roluperidone is still unclear, the analyst tells investors in a research note. The firm firm cites ongoing questions on the path forward and the need for additional funding for the target drop.